(19)
(11) EP 4 294 525 A1

(12)

(43) Date of publication:
27.12.2023 Bulletin 2023/52

(21) Application number: 21710375.3

(22) Date of filing: 17.02.2021
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
C07C 259/10(2006.01)
A61K 31/166(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/166; A61P 35/00; A61K 9/0056; A61K 9/14; A61K 9/20; A61K 9/16
(86) International application number:
PCT/US2021/018373
(87) International publication number:
WO 2022/177555 (25.08.2022 Gazette 2022/34)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(71) Applicant: Springworks Therapeutics, Inc.
Stamford, CT 06902 (US)

(72) Inventors:
  • PATTERSON, Kristin
    Stamford, Connecticut 06902 (US)
  • LIU, Jiping
    Stamford, Connecticut 06902 (US)

(74) Representative: Nederlandsch Octrooibureau 
P.O. Box 29720
2502 LS The Hague
2502 LS The Hague (NL)

   


(54) DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4- DIFLUORO-2-(2-FLUORO-4-IODO-PHENYLAMINO)-BENZAMIDE AND USES THEREOF